Phase 2 VEXAS Clinical Trials
3 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–3 of 3 trials
Recruiting
Phase 2
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
VEXAS SyndromeVEXAS
Swedish Orphan Biovitrum78 enrolled39 locationsNCT06782373
Recruiting
Phase 2
Momelotinib in VEXAS Syndrome
VEXAS SyndomeMyelo Dysplastic Syndrome
Groupe Francophone des Myelodysplasies57 enrolled11 locationsNCT07098936
Not Yet Recruiting
Phase 2
Efficacy of assigning treatment for participants with VEXAS syndrome with lenzilumab plus azacitidine
V - vacuoles are often seen in cells identified in bone marrow biopsies from patients with VEXAS syndrome.
E - E1 ubiquitin activating enzyme, encoded by the UBA1 gene which is mutated in patients
X - the UBA1 gene is located on the X chromosome.
A - patients have autoinflammation.
S - the mutations are somatic, meaning they are acquired at some point in life and not inherited.
(VEXAS)
South Australian Health & Medical Research Institute Ltd10 enrolled1 locationACTRN12625000619448